Cytisine–N-methylene-(5,7,4’-trihydroxy)- isoflavone ameliorates ischemic stroke-induced brain injury in mouse by regulating the oxidative stress and BDNF-Trkb/Akt pathway

• Published in: European journal of pharmacology Vol. 974; p. 176512
• Main Authors: Li, Yongbiao, Fan, Fangcheng, Liu, Qingshan
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 05.07.2024
• Subjects: Alkaloids - pharmacology; Alkaloids - therapeutic use; Animals; Azocines - pharmacology; BDNF-TrkB/Akt; Brain - drug effects; Brain - metabolism; Brain - pathology; Brain-Derived Neurotrophic Factor - metabolism; Cytisine–N-methylene-(5,7,4′-trihydroxy)- isoflavone; Disease Models, Animal; Ischemic stroke; Ischemic Stroke - complications; Ischemic Stroke - drug therapy; Ischemic Stroke - metabolism; Ischemic Stroke - pathology; Isoflavones - pharmacology; Isoflavones - therapeutic use; Male; Mice; Neuroprotective Agents - pharmacology; Neuroprotective Agents - therapeutic use; Oxidative stress; Oxidative Stress - drug effects; Oxygen–glucose deprivation/reperfusion; Proto-Oncogene Proteins c-akt - metabolism; Quinolizidine Alkaloids; Quinolizines - pharmacology; Quinolizines - therapeutic use; Receptor, trkB - metabolism; Signal Transduction - drug effects; Cytisine–N-methylene-(5,7,4′-trihydroxy)- isoflavone; Oxidative stress; BDNF-TrkB/Akt; Ischemic stroke; Oxygen–glucose deprivation/reperfusion
• ISSN: 0014-2999; 1879-0712
• DOI: 10.1016/j.ejphar.2024.176512

A novel compound Cytisine–N-methylene-(5,7,4′-trihydroxy)- isoflavone (LY01) found in the Sophora alopecuroides L is a neuroprotective agent. However, the effect and potential mechanism of LY01 treatment for ischemic stroke (IS) have not been fully elucidated. The aim of this study is to demonstrate whether LY01 can rescue ischemic stroke-induced brain injury and oxygen–glucose deprivation/reperfusion (OGD/R). Our results show that intragastric administration of LY01 improves ischemic stroke behaviors in mice, as demonstrated by neurological score, infarct volume, cerebral water content, rotarod test for activity. Compared with the model group, the ginkgo biloba extract (EGb) and LY01 reversed the neurological score, infarct volume, cerebral water content, rotarod test in model mice. Further analysis showed that the LY01 rescued oxidative stress in the model mice, which was reflected in the increased levels of catalase, superoxide dismutase, total antioxidant capacity and decreased levels of malondialdehyde in the serum of the model mice. Moreover, the expression of the brain-derived neurotrophic factor brain-derived neurotrophic factor (BDNF), phosphorylated protein kinase B (p-Akt), Bax, Bcl-2, (p)-tropomysin related kinase B (p-Trkb) was restored and the expression of Bax, glial fibrillary acidic protein (GFAP) in the brains of the model mice was inhibited through LY01 treatment. In the polymerase chain reaction (PCR) data, after giving LY01, the expression in the brains of model mice was that, IL-10 increased and IL-1β, Bax, Bcl-2 decreased. Furthermore, the results indicated that LY01 improved cell viability, reactive oxygen species content, and mitochondrial membrane potential dissipation induced by OGD/R in primary culture of rat cortical neurons. Bax and caspase-3 activity was upregulated compared to the before after treatment with LY01. Our study suggests that LY01 reversed ischemic stroke by reducing oxidative stress and activating the BDNF-TrkB/Akt pathway and exerted a neuroprotective action against OGD/R injury via attenuation, a novel approach was suggested to treat ischemic stroke. Our observations justify the traditional use of LY01 for a treatment of IS in nervous system. [Display omitted]